Oriana Nanni

Meldola, 47014, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 136 publications

Late-onset multiple sclerosis is associated with relapse-independent disability accrual: a propensity score-weighted recurrent-event study.

Late-onset multiple sclerosis is associated with relapse-independent disability accrual: a propensity score-weighted recurrent-event study.

Journal: Journal of neurology

Published: March 22, 2026

CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine.

CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine.

Journal: Frontiers in immunology

Published: November 28, 2025

Harmonized magnetic resonance imaging protocols for multiple sclerosis: HARMONY-MS, a pilot project.

Harmonized magnetic resonance imaging protocols for multiple sclerosis: HARMONY-MS, a pilot project.

Journal: Journal of neurology

Published: October 04, 2025

First real-world evidence from the Emilia-Romagna region suggests tamoxifen protects breast cancer patients from COVID-19.

First real-world evidence from the Emilia-Romagna region suggests tamoxifen protects breast cancer patients from COVID-19.

Journal: Scientific reports

Published: January 21, 2025

Transfemoral Transcatheter Aortic Valve Implantation at Hospitals Without On-Site Cardiac Surgery (TAVI at Home): A Multicenter Prospective Interventional Study.

Transfemoral Transcatheter Aortic Valve Implantation at Hospitals Without On-Site Cardiac Surgery (TAVI at Home): A Multicenter Prospective Interventional Study.

Journal: Journal of cardiovascular development and disease

Published: December 27, 2024

Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity.

Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity.

Journal: HLA

Published: July 09, 2024

Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study).

Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study).

Journal: Cancers

Published: April 15, 2024

Radiotherapy at the End of Life: From Retrospective Analysis to Strategies to Improve Outcomes.

Radiotherapy at the End of Life: From Retrospective Analysis to Strategies to Improve Outcomes.

Journal: Journal of pain and symptom management

Published: February 26, 2024

A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.

A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 08, 2024

Baseline and Longitudinal Neutrophil-to-Lymphocyte Ratio as Prognostic Factor for Metastatic Colorectal Cancer: A Secondary Analysis of the ITACa Randomized Trial.

Baseline and Longitudinal Neutrophil-to-Lymphocyte Ratio as Prognostic Factor for Metastatic Colorectal Cancer: A Secondary Analysis of the ITACa Randomized Trial.

Journal: JCO precision oncology

Published: January 31, 2024

Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study.

Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study.

Journal: Reviews in cardiovascular medicine

Published: December 08, 2023

A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).

A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).

Journal: Frontiers in oncology

Published: December 07, 2023

Showing 1-12 of 136

Last Updated: 09/26/2026